Time course of serum interleukin-6 concentration during longer duration polymyxin B-immobilized fiber column hemoperfusion

Time course of serum interleukin-6 concentration during longer duration polymyxin B-immobilized fiber column hemoperfusion - Time course of serum IL-6 concentration during longer duration PMX-DHP

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016654

Enrollment

Registered

2015-03-01

Start date

2015-03-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

septic shock

Interventions

Longer duration of polymyxin B-immobilized fiber column hemoperfusion (12 to 24 hours or occurrence of circuit coagulation) Conventional durationof polymyxin B-immobilized fiber column hemoperfusion (

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adult ICU patients with sepsis who need high dose catecholamine (catecholamine index equal to or higher than 10)

Exclusion criteria

Exclusion criteria: Patients who have allergy for polymyxin B Pregnant or lactating women Patients who want to withdraw or withheld the treatment Attending physicians' decision

Design outcomes

Primary

Measure	Time frame
Time course of serum IL-6 concentration during longer duration PMX-DHP	—

Secondary

Measure	Time frame
Time course of hemodynamic variables during longer duration PMX-DHP Time course of blood gas analysis results during longer duration PMX-DHP Time course of ventilation and oxygenation variables (FiO2, PaO2/FiO2) during longer duration PMX-DHP Renal function (BUN, Cre, eGFR), urinary output and need for renal replacement therapy Length of ICU stay, and length of hospital stay 28 day mortality Duration of mechanical ventilation Acute physiology and chronic health evaluation II (APACHE II) score, sequential organ failure assessment (SOFA) score, and disseminated intravascular coagulation (DIC) score by the Japanese Association for Acute Medicine (JAAM) Laboratory marker of inflammation (white blood cell, c-reactive protein, presepsin and procalcitonin) Duration of antimicrobial therapy	—

Measure

Time frame

Time course of hemodynamic variables during longer duration PMX-DHP Time course of blood gas analysis results during longer duration PMX-DHP Time course of ventilation and oxygenation variables (FiO2, PaO2/FiO2) during longer duration PMX-DHP Renal function (BUN, Cre, eGFR), urinary output and need for renal replacement therapy Length of ICU stay, and length of hospital stay 28 day mortality Duration of mechanical ventilation Acute physiology and chronic health evaluation II (APACHE II) score, sequential organ failure assessment (SOFA) score, and disseminated intravascular coagulation (DIC) score by the Japanese Association for Acute Medicine (JAAM) Laboratory marker of inflammation (white blood cell, c-reactive protein, presepsin and procalcitonin) Duration of antimicrobial therapy

—

Countries

Japan

Contacts

Public ContactKyohei Miyamoto

Wakayama Medical University Department of Emergency and Critical Care Medicine

go.go.kyohei.miyamoto@gmail.com0734410603

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026